Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets …
Dec 21 Biogen Inc said on Thursday one of its drug to treat Alzheimer's disease failed to meet the main goal of a mid-stage trial, sending the drugmaker's shares down 4.3 percent in premarket trading.
(Reuters) - Biogen Inc's second-quarter profit smashed estimates on Tuesday, boosted by strong sales of its spinal muscular atrophy (SMA) drug, Spinraza, which is priced at $750,000 for the first year of therapy. Buoyed by the …
Biogen Inc (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $318.33 to a high of $329.87. Yesterday, the shares gained 3.4%, which took the trading range above the 3-day high of $322.75 on volume of 361,000 …
Dec 22 (Reuters) - Biogen Inc ::BIOGEN RESPONDS TO COVERAGE RECOMMENDATION BY THE CANADIAN DRUG EXPERT COMMITTEE (CDEC) FOR SPINRAZA, THE ONLY TREATMENT APPROVED FOR TREATMENT OF 5Q …
The stock increased 2.90% or $2.75 during the last trading session ... upped its stake in Biogen Inc (NASDAQ:BIIB) by 3,781 shares to 9,483 shares, valued at $2.97 million in 2017Q3, according to the filing. It also increased its holding in …
The stock ended last trade at 43.00 a share and the price is up ... Carret Asset Mngmt Ltd Liability Company holds 53,814 shares or 0.48% of its portfolio. …